Bessemer Group’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14K | Sell |
175
-73
| -29% | -$4.69K | ﹤0.01% | 2085 |
|
|
2026
Q1 | $14K | Buy |
248
+12
| +5% | +$782 | ﹤0.01% | 2024 |
|
|
2025
Q4 | $19K | Sell |
236
-36
| -13% | -$2.42K | ﹤0.01% | 1894 |
|
|
2025
Q3 | $14K | Buy |
272
+63
| +30% | +$3.9K | ﹤0.01% | 1820 |
|
|
2025
Q2 | $16K | Buy |
209
+68
| +48% | +$4.5K | ﹤0.01% | 1640 |
|
|
2025
Q1 | $9K | Buy |
141
+16
| +13% | +$1.09K | ﹤0.01% | 1814 |
|
|
2024
Q4 | $10K | Sell |
125
-628
| -83% | -$50.4K | ﹤0.01% | 1764 |
|
|
2024
Q3 | $60K | Buy |
753
+201
| +36% | +$16.2K | ﹤0.01% | 1356 |
|
|
2024
Q2 | $46K | Buy |
552
+515
| +1,392% | +$45.3K | ﹤0.01% | 1287 |
|
|
2024
Q1 | $3K | Sell |
37
-9
| -20% | -$706 | ﹤0.01% | 1847 |
|
|
2023
Q4 | $4K | Sell |
46
-42
| -48% | -$3.63K | ﹤0.01% | 1823 |
|
|
2023
Q3 | $8K | Buy |
88
+46
| +110% | +$4.11K | ﹤0.01% | 1629 |
|
|
2023
Q2 | $4K | Buy |
+42
| New | +$3.55K | ﹤0.01% | 1867 |
|
|
2020
Q3 | – | Sell |
-44,800
| Closed | -$4.01M | – | 1474 |
|
|
2020
Q2 | $4.01M | Hold |
44,800
| – | – | 0.01% | 319 |
|
|
2020
Q1 | $4.46M | Buy |
44,800
+1,700
| +4% | +$184K | 0.02% | 292 |
|
|
2019
Q4 | $4.95M | Buy |
43,100
+300
| +0.7% | +$36.3K | 0.02% | 334 |
|
|
2019
Q3 | $5.4M | Buy |
42,800
+900
| +2% | +$114K | 0.02% | 282 |
|
|
2019
Q2 | $5.04M | Buy |
41,900
+7,000
| +20% | +$689K | 0.02% | 313 |
|
|
2019
Q1 | $3.05M | Buy |
34,900
+1,000
| +3% | +$90.9K | 0.01% | 365 |
|
|
2018
Q4 | $3.39M | Buy |
33,900
+5,700
| +20% | +$599K | 0.01% | 262 |
|
|
2018
Q3 | $3.23M | Sell |
28,200
-600
| -2% | -$62.1K | 0.01% | 304 |
|
|
2018
Q2 | $2.58M | Sell |
28,800
-2,500
| -8% | -$211K | 0.01% | 347 |
|
|
2018
Q1 | $2.29M | Sell |
31,300
-6,700
| -18% | -$460K | 0.01% | 378 |
|
|
2017
Q4 | $2.21M | Sell |
38,000
-20,700
| -35% | -$1.09M | 0.01% | 378 |
|
|
2017
Q3 | $2.63M | Buy |
58,700
+700
| +1% | +$29.1K | 0.01% | 383 |
|
|
2017
Q2 | $2.29M | Buy |
58,000
+400
| +0.7% | +$16.4K | 0.01% | 426 |
|
|
2017
Q1 | $2.34M | Hold |
57,600
| – | – | 0.01% | 456 |
|
|
2016
Q4 | $2.32M | Buy |
57,600
+2,900
| +5% | +$109K | 0.01% | 476 |
|
|
2016
Q3 | $1.98M | Buy |
+54,700
| New | +$1.88M | 0.01% | 450 |
|
|
2016
Q2 | – | Sell |
-46
| Closed | -$2K | – | 1362 |
|
|
2016
Q1 | $2K | Buy |
+46
| New | +$1.49K | ﹤0.01% | 1381 |
|
|
2014
Q3 | – | Sell |
-39
| Closed | -$1K | – | 1298 |
|
|
2014
Q2 | $1K | Buy |
+39
| New | +$1.3K | ﹤0.01% | 1351 |
|
|
2014
Q1 | – | Sell |
-92
| Closed | -$4K | – | 1328 |
|
|
2013
Q4 | $4K | Buy |
+92
| New | +$3.79K | ﹤0.01% | 1197 |
|
Other funds holding HAE
AI
Bessemer Group's HAE Position: Q2 2026 in Review
Bessemer Group reduced its Haemonetics (HAE) stake by 29% in Q2 2026, selling an estimated $4.69K and leaving 175 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #2085.
Bessemer Group first reported a position in HAE in Q4 2013 and has held it in 32 quarters since. The position peaked at $5.4M in Q3 2019. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- Bessemer Group held 175 shares of Haemonetics worth $14K as of Q2 2026.
- Bessemer Group sold 73 Haemonetics shares in Q2 2026, an estimated $4.69K.
- Haemonetics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2085 holding.
- Bessemer Group first reported a position in Haemonetics in Q4 2013 and has held it in 32 quarters since.
- Bessemer Group's Haemonetics position peaked at $5.4M in Q3 2019.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.